- Home
- PEN
PEN
Penumbra Inc.
as 05-09-2025 4:00pm EST
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 10.5B | IPO Year: | 2015 |
| Target Price: | $299.73 | AVG Volume (30 days): | 543.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.08 | EPS Growth: | -54.65 |
| 52 Week Low/High: | $148.00 - $310.00 | Next Earning Date: | 04-23-2025 |
| Revenue: | $1,240,100,000 | Revenue Growth: | 13.17% |
| Revenue Growth (this year): | 14.26% | Revenue Growth (next year): | 14.21% |
Stock Insider Trading Activity of Penumbra Inc. (PEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bose Arani | PEN | Director | Apr 25 '25 | Sell | $299.39 | 12,000 | $3,584,775.09 | 314,276 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 24 '25 | Sell | $300.01 | 600 | $180,006.00 | 66,159 | |
| Elsesser Adam | PEN | CEO and President | Apr 16 '25 | Sell | $274.69 | 16,560 | $4,543,228.37 | 75,629 | |
| O'Rourke Bridget | PEN | Director | Apr 15 '25 | Sell | $271.21 | 50 | $13,560.50 | 5,523 | |
| Wilder Thomas | PEN | Director | Apr 2 '25 | Sell | $266.93 | 360 | $96,094.80 | 4,692 | |
| Elsesser Adam | PEN | CEO and President | Apr 2 '25 | Sell | $272.32 | 16,565 | $4,509,728.21 | 75,629 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 1 '25 | Sell | $267.89 | 600 | $161,466.15 | 66,159 | |
| Grewal Harpreet | PEN | Director | Apr 1 '25 | Sell | $267.17 | 200 | $53,434.00 | 9,074 | |
| Wilder Thomas | PEN | Director | Mar 31 '25 | Sell | $264.58 | 360 | $95,248.80 | 4,692 | |
| Bose Arani | PEN | Director | Mar 25 '25 | Sell | $284.79 | 12,000 | $3,405,252.50 | 314,276 |
Latest Penumbra Inc. News
PEN Breaking Stock News: Dive into PEN Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
PEN: Lowering target price to $307.00
Investor's Business Daily
7 days ago
Spotify Breaks Out After Apple Ruling, Leads 5 Stocks Near Buy Points
StockStory
9 days ago
3 Profitable Stocks in the Doghouse
PR Newswire
10 days ago
Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference
Zacks
11 days ago
3 Reasons Growth Investors Will Love Penumbra (PEN)
Zacks
11 days ago
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
Simply Wall St.
13 days ago
Penumbra, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Simply Wall St.
15 days ago
Penumbra First Quarter 2025 Earnings: Beats Expectations
Compare PEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PEN Penumbra Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.